{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:31:39Z","timestamp":1788193899547,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.imbio.2023.152378","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:26:24Z","timestamp":1679628384000},"page":"152378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-9449","authenticated-orcid":false,"given":"Kurosh","family":"Kalantar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefe","family":"Ghamar Talepoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Eshkevar Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Kalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Ghandehari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Kabelitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Meri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afagh","family":"Moattari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2023.152378_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.741502","article-title":"Defining the innate immune responses for SARS-CoV-2-human macrophage interactions","volume":"12","author":"Abdelmoaty","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2023.152378_b0010","doi-asserted-by":"crossref","unstructured":"Asrani P., Hassan M.I. 2021. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions. 476(2): 675\u2013687.","DOI":"10.1007\/s11010-020-03935-z"},{"key":"10.1016\/j.imbio.2023.152378_b0015","doi-asserted-by":"crossref","unstructured":"Beigel J.H., et al. 2020. Remdesivir for the Treatment of Covid-19 - Final Report. 383(19): 1813-1826.","DOI":"10.1056\/NEJMc2022236"},{"key":"10.1016\/j.imbio.2023.152378_b0020","doi-asserted-by":"crossref","unstructured":"Biancofiore A., Mirijello A., 2022. Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: A retrospective case-control study. 94(5): 2284-2289.","DOI":"10.1002\/jmv.27598"},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pulmoe.2021.03.008","article-title":"The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives","volume":"27","author":"Boechat","year":"2021","journal-title":"Pulmonology"},{"key":"10.1016\/j.imbio.2023.152378_b0030","unstructured":"Bouscambert-Duchamp M. J. Antimicrob. Chemother."},{"key":"10.1016\/j.imbio.2023.152378_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680188","article-title":"Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir","volume":"12","author":"Chan","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.imbio.2023.152378_b0045","first-page":"471","article-title":"Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019","volume":"36","author":"Chen","year":"2020","journal-title":"Zhonghua Shao Shang Za Zhi"},{"key":"10.1016\/j.imbio.2023.152378_b0050","unstructured":"Coronavirus N., Infections Trigger an Exaggerated Cytokine Response Aggravating Lung Injury. 2019."},{"issue":"1","key":"10.1016\/j.imbio.2023.152378_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12879-022-07079-x","article-title":"Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude","volume":"22","author":"Del Valle-Mendoza","year":"2022","journal-title":"BMC Infect. Dis."},{"issue":"7","key":"10.1016\/j.imbio.2023.152378_b0060","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.imbio.2023.152378_b0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/pathogens11020195","article-title":"The association between TNF-\u03b1, IL-6, and vitamin D levels and COVID-19 severity and mortality: A systematic review and meta-analysis","volume":"11","author":"Halim","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.imbio.2023.152378_b0070","doi-asserted-by":"crossref","unstructured":"Han H., et al. 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. 9(1): 1123-1130.","DOI":"10.1080\/22221751.2020.1770129"},{"issue":"2","key":"10.1016\/j.imbio.2023.152378_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/ecn.2022.0477","article-title":"Th1 cytokine endotype discriminates and predicts severe complications in COVID-19","volume":"33","author":"Hasegawa","year":"2022","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.imbio.2023.152378_b0080","doi-asserted-by":"crossref","unstructured":"Hojyo S., et al., 2020. How COVID-19 induces cytokine storm with high mortality. 40: 37.","DOI":"10.1186\/s41232-020-00146-3"},{"key":"10.1016\/j.imbio.2023.152378_b0085","article-title":"Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: A systematic review and meta-analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"10223","key":"10.1016\/j.imbio.2023.152378_b0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.imbio.2023.152378_b0100","article-title":"Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia","volume":"10","author":"Judge","year":"2022","journal-title":"SAGE Open Med. Case Rep."},{"key":"10.1016\/j.imbio.2023.152378_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771609","article-title":"A deep look into COVID-19 severity through dynamic changes in blood cytokine levels","volume":"12","author":"Kleymenov","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.imbio.2023.152378_b0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jinf.2022.08.031","article-title":"Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis","volume":"85","author":"Lai","year":"2022","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/jac\/dkac048","article-title":"Effect of Remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial","volume":"77","author":"Lingas","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.imbio.2023.152378_b0120","doi-asserted-by":"crossref","unstructured":"Liu Q.Q., et al. 2020. Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study. 10(11): e041471.","DOI":"10.1136\/bmjopen-2020-041471"},{"issue":"1","key":"10.1016\/j.imbio.2023.152378_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05792-7","article-title":"Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.imbio.2023.152378_b0130","doi-asserted-by":"crossref","unstructured":"Merza M.Y., et al. 2021. Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq. 16(4): e0250330.","DOI":"10.1371\/journal.pone.0250330"},{"key":"10.1016\/j.imbio.2023.152378_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107407","article-title":"Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra","volume":"93","author":"Mortaz","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.imbio.2023.152378_b0140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0145","first-page":"436","article-title":"Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions","volume":"9","author":"Rabaan","year":"2021","journal-title":"Immunopathol. Immunomodul. Drugs Counter Cytokine Storm"},{"issue":"1","key":"10.1016\/j.imbio.2023.152378_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-11157-0","article-title":"In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection","volume":"12","author":"Romano","year":"2022","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.imbio.2023.152378_b0155","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: What's next?","volume":"177","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.imbio.2023.152378_b0160","doi-asserted-by":"crossref","unstructured":"Schloer S., Brunotte L., 2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. 178(11): 2339\u20132350.","DOI":"10.1111\/bph.15418"},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"issue":"1","key":"10.1016\/j.imbio.2023.152378_b0170","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jmv.27280","article-title":"Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with Remdesivir","volume":"94","author":"Stoeckle","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.imbio.2023.152378_b0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9-10","key":"10.1016\/j.imbio.2023.152378_b0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000518440","article-title":"Remdesivir: A closer look at its effect in COVID-19 pandemic","volume":"106","author":"Taha","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.imbio.2023.152378_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155523","article-title":"Aberrant cytokine expression in COVID-19 patients: Associations between cytokines and disease severity","volume":"143","author":"Tang","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.imbio.2023.152378_b0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.imbio.2023.152378_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964179","article-title":"Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study","volume":"13","author":"Tufa","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2023.152378_b0200","article-title":"In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.imbio.2023.152378_b0205","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.imbio.2023.152378_b0210","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiaa387","article-title":"Definition and risks of cytokine release syndrome in 11 critically ill COVID-19 patients with pneumonia: analysis of disease characteristics","volume":"222","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.imbio.2023.152378_b0215","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.imbio.2023.152378_b0220","doi-asserted-by":"crossref","unstructured":"Yang L., et al. 2021. The signal pathways and treatment of cytokine storm in COVID-19. 6(1): 255.","DOI":"10.1038\/s41392-021-00679-0"},{"issue":"5","key":"10.1016\/j.imbio.2023.152378_b0225","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.imbio.2023.152378_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198137","article-title":"Effect of Remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials","volume":"288","author":"Yokoyama","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.imbio.2023.152378_b0235","article-title":"Cellular immune response to COVID-19 and potential immune modulators","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.imbio.2023.152378_b0240","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2023.152378_b0095","doi-asserted-by":"crossref","unstructured":"Izcovich A., Siemieniuk R.A. 2022. Adverse effects of remdesivir, hydroxychloroquine and lopinavir\/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. 12(3): e048502.","DOI":"10.1136\/bmjopen-2020-048502"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298523000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298523000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:51:51Z","timestamp":1759251111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298523000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0171298523000463"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2023.152378","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2023.152378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152378"}}